Literature DB >> 35275752

Tim-3 adapter protein Bat3 acts as an endogenous regulator of tolerogenic dendritic cell function.

Ruihan Tang1,2, Nandini Acharya1,2, Ayshwarya Subramanian1,2,3, Vinee Purohit1,2, Marcin Tabaka3, Yu Hou1,2, Danyang He1,2, Karen O Dixon1,2, Connor Lambden1,2, Junrong Xia1,2, Orit Rozenblatt-Rosen3, Raymond A Sobel4, Chao Wang1,2, Aviv Regev3,5, Ana C Anderson1,2, Vijay K Kuchroo1,2,3.   

Abstract

Dendritic cells (DCs) sense environmental cues and adopt either an immune-stimulatory or regulatory phenotype, thereby fine-tuning immune responses. Identifying endogenous regulators that determine DC function can thus inform the development of therapeutic strategies for modulating the immune response in different disease contexts. Tim-3 plays an important role in regulating immune responses by inhibiting the activation status and the T cell priming ability of DC in the setting of cancer. Bat3 is an adaptor protein that binds to the tail of Tim-3; therefore, we studied its role in regulating the functional status of DCs. In murine models of autoimmunity (experimental autoimmune encephalomyelitis) and cancer (MC38-OVA-implanted tumor), lack of Bat3 expression in DCs alters the T cell compartment-it decreases TH1, TH17 and cytotoxic effector cells, increases regulatory T cells, and exhausted CD8+ tumor-infiltrating lymphocytes, resulting in the attenuation of autoimmunity and acceleration of tumor growth. We found that Bat3 expression levels were differentially regulated by activating versus inhibitory stimuli in DCs, indicating a role for Bat3 in the functional calibration of DC phenotypes. Mechanistically, loss of Bat3 in DCs led to hyperactive unfolded protein response and redirected acetyl-coenzyme A to increase cell intrinsic steroidogenesis. The enhanced steroidogenesis in Bat3-deficient DC suppressed T cell response in a paracrine manner. Our findings identified Bat3 as an endogenous regulator of DC function, which has implications for DC-based immunotherapies.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 35275752      PMCID: PMC9273260          DOI: 10.1126/sciimmunol.abm0631

Source DB:  PubMed          Journal:  Sci Immunol        ISSN: 2470-9468


  83 in total

1.  Retinoic acid primes human dendritic cells to induce gut-homing, IL-10-producing regulatory T cells.

Authors:  G Bakdash; L T C Vogelpoel; T M M van Capel; M L Kapsenberg; E C de Jong
Journal:  Mucosal Immunol       Date:  2014-07-16       Impact factor: 7.313

2.  Hypercholesterolemia Induces Differentiation of Regulatory T Cells in the Liver.

Authors:  Reiner K W Mailer; Anton Gisterå; Konstantinos A Polyzos; Daniel F J Ketelhuth; Göran K Hansson
Journal:  Circ Res       Date:  2017-04-18       Impact factor: 17.367

Review 3.  Dendritic cells in cancer immunology and immunotherapy.

Authors:  Stefanie K Wculek; Francisco J Cueto; Adriana M Mujal; Ignacio Melero; Matthew F Krummel; David Sancho
Journal:  Nat Rev Immunol       Date:  2019-08-29       Impact factor: 53.106

Review 4.  The dendritic cell lineage: ontogeny and function of dendritic cells and their subsets in the steady state and the inflamed setting.

Authors:  Miriam Merad; Priyanka Sathe; Julie Helft; Jennifer Miller; Arthur Mortha
Journal:  Annu Rev Immunol       Date:  2013       Impact factor: 28.527

5.  XBP-1 regulates a subset of endoplasmic reticulum resident chaperone genes in the unfolded protein response.

Authors:  Ann-Hwee Lee; Neal N Iwakoshi; Laurie H Glimcher
Journal:  Mol Cell Biol       Date:  2003-11       Impact factor: 4.272

6.  A ribosome-associating factor chaperones tail-anchored membrane proteins.

Authors:  Malaiyalam Mariappan; Xingzhe Li; Sandra Stefanovic; Ajay Sharma; Agnieszka Mateja; Robert J Keenan; Ramanujan S Hegde
Journal:  Nature       Date:  2010-08-01       Impact factor: 49.962

7.  The role of glucocorticoid receptor (GR) polymorphisms in human erythropoiesis.

Authors:  Lilian Varricchio; Anna Rita Migliaccio
Journal:  Am J Blood Res       Date:  2014-12-15

8.  Protein targeting and degradation are coupled for elimination of mislocalized proteins.

Authors:  Tara Hessa; Ajay Sharma; Malaiyalam Mariappan; Heather D Eshleman; Erik Gutierrez; Ramanujan S Hegde
Journal:  Nature       Date:  2011-07-10       Impact factor: 49.962

9.  IRE1α-XBP1s pathway promotes prostate cancer by activating c-MYC signaling.

Authors:  Xia Sheng; Hatice Zeynep Nenseth; Su Qu; Omer F Kuzu; Turid Frahnow; Lukas Simon; Stephanie Greene; Qingping Zeng; Ladan Fazli; Paul S Rennie; Ian G Mills; Håvard Danielsen; Fabian Theis; John B Patterson; Yang Jin; Fahri Saatcioglu
Journal:  Nat Commun       Date:  2019-01-24       Impact factor: 14.919

10.  Structure and mechanism of action of the hydroxy-aryl-aldehyde class of IRE1 endoribonuclease inhibitors.

Authors:  Mario Sanches; Nicole M Duffy; Manisha Talukdar; Nero Thevakumaran; David Chiovitti; Marella D Canny; Kenneth Lee; Igor Kurinov; David Uehling; Rima Al-awar; Gennadiy Poda; Michael Prakesch; Brian Wilson; Victor Tam; Colleen Schweitzer; Andras Toro; Julie L Lucas; Danka Vuga; Lynn Lehmann; Daniel Durocher; Qingping Zeng; John B Patterson; Frank Sicheri
Journal:  Nat Commun       Date:  2014-08-28       Impact factor: 14.919

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.